Sodium-glucose cotransporter 2 inhibitors for chronic heart failure: The ultimate solution?
- PMID: 37349853
- DOI: 10.1002/ejhf.2942
Sodium-glucose cotransporter 2 inhibitors for chronic heart failure: The ultimate solution?
Comment on
-
Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study.Eur J Heart Fail. 2023 Aug;25(8):1352-1360. doi: 10.1002/ejhf.2884. Epub 2023 Jun 7. Eur J Heart Fail. 2023. PMID: 37211950
References
-
- Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2021 update: A report from the American Heart Association. Circulation. 2021;143:e254-e743. https://doi.org/10.1161/CIR.0000000000000950
-
- Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: A population-based study of 4 million individuals. Lancet. 2018;391:572-580. https://doi.org/10.1016/S0140-6736(17)32520-5
-
- Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: A review. Diabetes Metab Res Rev. 2005;21:31-38. https://doi.org/10.1002/dmrr.532
-
- Hjarne U. A study of orthoglycaemic glycosuria with particular reference to its hereditability. Acta Med Scand. 1927;67:495-571.
-
- Santer R, Calado J. Familial renal glucosuria and SGLT2: From a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5:133-141. https://doi.org/10.2215/CJN.04010609
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical